Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer.

about

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q55119011

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Progression-free survival as a ...... metastatic colorectal cancer.

@en

Progression-free survival as a ...... metastatic colorectal cancer.

@nl

type

Item

label

Progression-free survival as a ...... metastatic colorectal cancer.

@en

Progression-free survival as a ...... metastatic colorectal cancer.

@nl

prefLabel

Progression-free survival as a ...... metastatic colorectal cancer.

@en

Progression-free survival as a ...... metastatic colorectal cancer.

@nl

P1476

Progression-free survival as a ...... h metastatic colorectal cancer

@en

P2093

Giuseppe Cicero

http://www.w3.org/2001/XMLSchema#string

P2860

Role of targeted therapy in metastatic colorectal cancer

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.

Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.

P304

3059-3063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S151276

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Dieli

Rossella De Luca

P577

2018-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29872317

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5975605

http://www.w3.org/2001/XMLSchema#string